

***EAPM Presidency Conference
Determining a path for optimal integration of Access & Diagnostics for All &
Public Health Genomics***

Tuesday, April 5th, 2022

09.00 – 16.00 CET

Background

Personalised medicine and targeted biomarkers have the potential to revolutionise not only the treatment but also the prevention of malignancy, and advances in targeted therapies have changed clinical practice for some diseases. For healthcare professionals, biomarker testing provides a deeper analysis of the disease to differentiate the diagnosis and provide direction on the application of specific treatments. For patients it expands the chances of successful treatment, provides knowledge about their condition, and widens and allows for stratification of the choices after diagnosis. And for policy makers, it can identify and reduce disease risk, through prevention, early detection and treatment identification, as well as monitoring the effectiveness and choice of treatments.

For the health-care system as a whole, biomarkers could make it possible to avoid using new and often expensive drugs in patients that are not going to benefit from them, thus contributing to health system sustainability.

It can also contribute to reduce waste, e.g. via avoidance of unnecessary administration of antibiotics. The effective use of biomarkers can contribute to a two-fold objective: maintaining health system sustainability, while providing high-value care. For some diseases biomarkers serving as molecular targets for Precision Medicine have totally changed overall survival and outcome in formerly devastating cancer diseases, i.e. *bcr/abl* in Chronic Myeloid Leukemia, *c-kit* mutations in Gastrointestinal Stromal Tumours or *EGFR* mutations in Lung Cancer.

Alignment with European Union, Member State and Other Relevant Activities

The conference will actively look to align with and develop EU and Member State work on personalised medicine, genomics, and relevant areas of healthcare, data and informatics more broadly.

It will also look to engage medical and genetics professional bodies, patient representative organisations, disease-specific charities and organisations, and all other relevant bodies to get a broad range of perspectives on this area and aggregate existing guidance.

Sessions will include:

- Opening Session: Public Health and Genomics: the future is already here
- Plenary Session I: Bringing innovation into Healthcare Systems
- Plenary Session II: Molecular Diagnostics, Screening and Early Diagnosis to the Fore
- Plenary Session III: Diagnosis and Treating Patients
- Closing Session

Presidency Conference Event

This conference will take on Tuesday, April 5th, 2022, bringing together policy makers with thought leaders from healthcare, academia, industry, and patient organisations, to learn from each other and discuss the current state of play and a joint approach forward to developing widespread development and adoption best practice.

Together we have the opportunity to facilitate the appropriate use of genomics and genomic data that will maximise the benefit to health systems and patient care.



Expected outcomes

The main outcome will feed into activity that will support this action at the national level.

- to assess and address obstacles to the integration of personalised medicine into Europe's healthcare systems
- to identify best practices and their added value
- to outline the potential benefits of personalised medicine on public health and its impact on policymaking in the EU

Participants

Attendees will be drawn from key stakeholders whose interaction will create a cross-sectoral, highly relevant and dynamic discussion forum. These participants will include public health decision makers, representatives from the European Commission, Members of the Parliament, patient organisations, and umbrella organisations representing interest groups and associations actively engaged in the field. Each session will comprise panel discussions as well.

Determining a path for optimal integration of Access & Diagnostics for All & Public Health Genomics

Tuesday, April 5th, 2022

09.00 – 16.00 CET

09:00 -10:00	Opening Session: Public Health and Genomics: the future is already here
--------------	--

State of Health in the EU –

John Ryan, *Director, Public Health, Country Knowledge and Crisis Management, DG SANTE*

Public Health

Natasha Azzopardi Muscat, *Director, Division of Country Health Policies and Systems at WHO EURO. (Confirmed)*

Public Trust and Public Health

Bettina Borisch, *Executive Director World Federation of Public Health Associations (WFPHA) (Confirmed)*

Ethics

Bogi Eliassen, *Director of Health/Head of Denmark Unit UNESCO Chair in Bioethics (confirmed)*

Genomics, Genomics, Genomics

Peter Kaptiein, *Inspire2Life. (confirmed)*

Discussion

10.00-11:30	Plenary Session I: Bringing innovation into Healthcare Systems
-------------	---

Chair: **Denis HORGAN**, *European Alliance for Personalised Medicine*

10:00 -10.10 **International Frameworks**

Andrew Biankin, *Regius Chair of Surgery/Director of Translational Research Centre, University of Glasgow (Confirmed)*

10:10 -10.20 **Making it Happen: Stakeholder Perspectives:**
Stefan Gijssels, *Patient Expert Center (PEC), Belgium (Confirmed)*

10.20 -10.30 Health System – EU Perspective
Marc Van den Bulcke, *Cancer Centre – Sciensano – Belgium. (Confirmed)*

10.30 -10.40 Molecular Tumour Boards
Benedikt Westphalen. *Head of Molecular Diagnostics and Therapy Program and the Molecular Tumour Board, Comprehensive Cancer Centre, University Munich, Germany (Confirmed)*

10.40 -10.50 Public Health Genomics
Stefania Boccia, *Director, Section of Hygiene, University Department of Health Sciences and Public Health,, Faculty of Medicine, Università Cattolica del Sacro Cuore, Fondazione Policlinico ‘Agostino Gemelli’ IRCCS. (Confirmed)*

10:50 -11.00. Best Practices in Bring Innovation into HealthCare Systems
Ejner Moltzen, *Chair of ICPeMed (Confirmed)*

11:10 -11.20. **Translational Research to Action**
Michael Zaiac, *Head of Medical Affairs Oncology Region Europe, Novartis (Confirmed)*

11.20 -11.40 Followed by Q&A – Identifying key areas of commonality and areas of differences between the varied perspectives

11.40 - 11.45 BREAK

11.45 -13:15	Plenary Session II: Molecular Diagnostics, Screening and Early Diagnosis to the Fore
--------------	---

Chair: Denis HORGAN, European Alliance for Personalised Medicine

11:45 -11:55 **Why Now?**
Rosa Giuliani, *Director of Public Policy at the European Society for Medical Oncology (ESMO), Consultant medical oncologist, The Clatterbridge Cancer Centre NHS Foundation Trust (Confirmed)*

11:55 -12:05 **Patient Perspective**
Barbara Moss, *Patient Ambassador for Digestive Cancer Europe and Bowel Cancer UK. (confirmed)*

12:05 -12:15 **Italian Approach**
Ruggero De Maria, MD, *President, Alleanza Contro il Cancro . (confirmed)*

12:15 -12:25 **French National Cancer Plan**
Frédérique Nowak, *Coordination du Plan France Médecine Génomique 2025, Inserm. (confirmed)*



12.25 – 12.35

German Approach

Olaf Riess, *Institute of Medical Genetics and Applied Genomics, University of Tübingen, Germany.*
(Confirmed)

12.35 – 12.45

Romanian Approach

Marius Gaenta, Co-Founder, Center for Innovation in Medicine, Bucharest, Romania (confirmed)

12.45 – 12.55

Screening and Early Diagnosis

MSD Speaker

12:55 -13:15

Panel Discussion: What do we want from you? How Can This be Supported

13.15 – 14.00

Lunch

14:05 -15:45 **Plenary Session III: Diagnosis and Treating Patients**

14.00 -14:05

Chair: Denis HORGAN, *European Alliance for Personalised Medicine*

14.05 -14:15

Thyroid Cancer

Furio Pacini, *Professor, Director of Endocrinology at University of Siena, Italy (Confirmed)*

14.15 -14:25

Role of Pathology

Frederique Penault-Llorca, *Director, Centre de Lutte Contre le Cancer de Clermont-Ferrand, France*

14:25 -14:35

Data, Data, Data

Mario Romao, *EMEA Global Public Policy team, Intel (Confirmed)*

14:45 -14:55

Rare Cancers

Paolo Casali, *Rare Cancer Europe, European Society of Medicine Oncology (Confirmed)*

14:55 -15:05

Blood Cancers

Giovanni Martinelli, M.D., *Hematology Professor, Institute of Hematology, "L. and A. Seràgnoli", S. Orsola University Hospital, Italy (Confirmed)*

15:05 -15:15

Role of the EU

Antoni Montserrat Moliner, *Active Senior on Public Health for the European Commission (Confirmed)*

15:15 -15:45

Followed by Q&A – How do we further different models of national development and what is the EU role in coordinating and supporting this?

15:45– 16.00 **Conclusion: Next Steps**